Drug intelligence / Profile preview

RT1002

Development stage: Preclinical
Lead developer: Jiangsu Rongtai Biotech
Modality: Recombinant Proteins and Enzymes

Overview

RT1002 is an investigational drug candidate currently in the preclinical stage of development by Jiangsu Rongtai Biotech (JSRT Biotech). It is being developed for the treatment of various inflammatory diseases. While specific details regarding its molecular target, mechanism of action, and modality have not been publicly disclosed in detail, the developer's core technological focus is primarily on recombinant protein engineering and genetic expression systems. As a preclinical asset, RT1002 is undergoing early-stage laboratory and animal studies to evaluate its therapeutic potential and safety profile in managing inflammation.

Beyond the preview

Go deeper on RT1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT1002.

Explore the full profile